Table 4

Effect of cisplatin i.v. (q2dx2) in combination with ALC p.o. (qdx14) on tumor growth, on median survival time, and on development of metastases in C57/BL6J male mice bearing a transplantable 3LL lung carcinoma

Cisplatin was administered one day after the tumor injection. ALC treatment started on the same day as tumor injection.

TreatmentDose (mg/kg)BWL%a maxTVI%bMSTc (range in days)ILS%Metastases/lungs ± SE
Controlsd0148.0 ± 1.1
(14–24)
ALC1000217216.7 ± 0.3
(13–23)
Cisplatin65461721e1.3 ± 0.8
(14–27)
ALC + cisplatin100 + 61140f2043e2.5 ± 0.9
(14–23)
Cisplatin81160g2686e1.1 ± 0.7
(18–29)
ALC + cisplatin100 + 81063g2686e0.7 ± 0.5
(15–28)
  • a BWL%, maximum body weight loss during the experimental period.

  • b TVI, tumor volume inhibition was calculated 8 days after the last treatment with cisplatin.

  • c MST, median survival time (days).

  • d Controls, vehicle-treated group.

  • e P < 0.01 versus vehicle (Mann-Whitney).

  • f P < 0.05 versus vehicle (Mann-Whitney).

  • g P < 0.001 versus vehicle (Mann-Whitney).